Statin Use After Heart Transplantation
Meta-Analysis). 15 A checklist of each of the PRISMA criteria and how they were handled in our study is contained in Table  I in the Data Supplement. The methodological quality of the studies was assessed using the Downs and Black checklist. 16 
Data Sources
We searched PubMed, Cochran CENTRAL, and Web of Science databases from their inception to June 1, 2015. We used the following terms "cardiac transplant" or "heart transplant" and "statin" for a literature search. Reference lists from relevant articles were reviewed to identify additional studies. Studies in languages other than English were not included.
Study Selection
Clinical trials were included in the meta-analysis if the following criteria were met: (1) studies that reported any of the following clinical outcomes in both treatment arms: mortality, hemodynamically significant or fatal rejection, coronary vasculopathy, terminal malignancy, and myopathy; (2) minimum follow-up period of at least 1 year; and (3) studies involving predominantly adult subjects (age >18 years). Case reports, editorials, case series, and review articles were not included. Studies with <5 patients in either treatment arm were not included.
Data Extraction
The titles and abstracts were screened for relevance by 2 independent reviewers (A.V. and S.R.). Differences between reviewers were discussed until consensus was reached. The manuscripts of selected titles/abstracts were assessed for inclusion, and the authors were contacted if further information was required. Using the selection criteria enlisted above, the 2 reviewers independently identified the papers to be included and excluded, and data from the included papers were extracted using predefined extraction flow sheets. Any differences in data extraction were discussed until agreement between both reviewers was reached. If a study compared different statins with statin-naive cohort, the data of all statins was combined into a single group for pooled analysis.
Data Analysis
Statistical analysis was performed with Review Manager (RevMan) software, version 5.2 (Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2012). A random-effects model with Mantel-Haenszel method was used to calculate pooled odds ratio and 95% confidence interval (CI). We assessed 5 outcomes: (1) mortality, (2) hemodynamically significant or fatal rejection, (3) coronary vasculopathy, (4) terminal malignancy, and (5) myopathy. Transplant vasculopathy, progression of coronary artery disease on intravascular ultrasound or death attributed to coronary artery disease, was defined as coronary vasculopathy. Death secondary to malignancy was designated as terminal cancer. Elevation of creatine phosphokinase above the upper limit of normal or rhabdomyolysis was defined as myopathy. Heterogeneity between studies was assessed using Cochran Q test and I 2 statistic, which by guest on August 24, 2017 http://circheartfailure.ahajournals.org/ Downloaded from denotes the percentage of total variation across studies that are a result of heterogeneity rather than chance. Heterogeneity was considered significant if the P value for the heterogeneity test was <0.05. Publication bias was assessed by visual inspection of funnel plots and Egger regression test. The influence of individual studies was examined by removing each study at a time to assess the degree to which the meta-analysis estimate depended on a particular study (exclusion sensitivity analysis).
Results

Study Outlines and Characteristics
We identified 10 studies 1,2,4,8-11,17-20 ( Figure 1 ), 4 randomized controlled trials and 6 nonrandomized studies, which compared outcomes in heart transplant recipients undergoing statin therapy to the outcomes in statin-naive patients.
Ten-year follow-up of landmark study 7 by Kobashigawa et al 1 was published in 2005, and the data from the first study was included in meta-analysis. The pooled analysis included a total of 2295 heart transplant patients, of which 1635 received statin therapy and 660 did not receive statins. Details of the studies are reported in Table. The duration of follow-up in the included studies ranged from 12 months to 12 years. The quality of the included studies evaluated by the Downs and Black assessment method is presented in Table II in the Data Supplement.
Total Mortality
The pooled analysis of 9 studies reporting mortality in heart transplant recipients revealed that the use of statins was associated with significant reduction in all-cause mortality (odds ratio [OR], 0.26; 95% CI, 0.20-0.35; P<0.0001; Figure 2 ). There was no significant heterogeneity across the studies (P=0.84; I 2 =0%). There was no appreciable publication bias on inspection of the funnel plot ( Figure I in the Data Supplement) or with the regression test of Egger (P=0.39). Sensitivity analysis did not reveal any significant change in effect size with the exclusion of any particular study. We further explored the robustness of our findings by changing the meta-analysis method from a random-to fixed-effects model. There was no change in summary effect size with fixed-effects model 
Hemodynamically Significant/Fatal Rejection
Eight studies reported the effect of statins on hemodynamically significant/fatal rejection in heart transplant recipients. No significant heterogeneity was noted across the studies (P=0.27; I 2 =20%). Pooled analysis revealed that statins decreased the odds of hemodynamically significant/fatal rejection (OR, 0.37; 95% CI, 0.21-0.65; P=0.0005; Figure 3 
Coronary Vasculopathy
Four studies reported the impact of statins on coronary vasculopathy in heart transplant recipients. The average duration of follow-up in these 4 studies was 2.75 years. There was no significant heterogeneity across the studies (P=0.97; I 
Myopathy
The pooled analysis of 5 studies reporting myopathy in heart transplant recipients revealed that the use of statins was not associated with increased risk of myopathy (OR, 1.70; 95% CI, 0.68-4.24; P=0.25; Figure 6 ). There was no significant heterogeneity across the studies (P=0.38; I 2 =0%). Publication bias could not be assessed as there were no events reported in the either arm in 3 studies. There was no change in summary effect size with omitting 1 study at a time or fixedeffects model. The outcomes from studies by Fröhlich et al 9 (5/151) and Grigioni et al 20 (6/186) were not included in the pooled analysis because these 2 studies reported the rates of myopathy only in heart transplant recipients undergoing statin therapy.
Discussion
There are 2 main findings of this study. First, statins provide substantial survival benefit and reduce hemodynamically significant rejection episodes in heart transplant recipients. Second, the use of statins is associated with lower incidence of coronary vasculopathy and terminal cancer.
To our knowledge, this is the largest meta-analysis involving a total of 2295 patients and evaluating the impact of statins in heart transplant recipients. A previous meta-analysis reported significant survival benefit with statin therapy in heart transplant recipients (relative risk 0.31; 95% CI, 0.13-0.7; P=0.006). 21 The sample size of this pooled analysis of 3 studies involving only 246 patients was relatively small. Furthermore, only 2 (mortality and rejection) outcomes were studied in this pooled analysis.
Current guidelines strongly recommend (Class I; Level of Evidence A) initiation of statins within 1 to 2 days of heart transplantation, irrespective of lipid profile. 3 Statins may improve survival in heart transplant recipients because of reductions of cholesterol levels. In porcine heart transplant models, dietinduced hypercholesterolemia resulted in accelerated allograft vessel intimal hyperplasia and increased lipid deposition. 22 In heart transplant patients, statins not only reduce cholesterol levels but also decrease the incidence of graft atherosclerosis. 1, 18 Alternatively, cholesterol-independent effects of statins also play a major role in inhibiting allograft coronary artery vasculopathy, which occurs via mechanisms other than atherosclerosis. In murine heart transplant models, statins have been shown to promote atherosclerotic plaque stabilization. 23 Statins downregulate nitric oxide synthase II gene expression that influences endothelial nitric oxide production. 24 In heart transplant recipients, statin also improve coronary endothelial function. 25 Through inhibition of 3-hydroxy-3-methylglutarylcoenzyme A reductase, statins decrease the synthesis of mevalonate and other prenylated proteins, farnesyl pyrophosphate and geranyl pyrophosphate, which mediate intracellular signal transduction. This leads to inhibition of protein biosynthesis, which in turn attenuates the proliferation of vascular smooth muscle tissue. 26 Statins also downregulate the expression of growth factor genes, which are important for production of smooth muscle cells. 24, 26 Our study showed that statins decreased the incidence of coronary vasculopathy and hemodynamically significant rejection episodes by 67% and 63%, respectively. Different hypotheses have been proposed to explain the potential immunomodulatory role of statins. 5, [27] [28] [29] Statins promote suppression of natural killer cell activity. 5 Statins dramatically reduce lipoprotein levels, which results in higher concentration of unbound fraction of immunosuppressive drug, cyclosporine. 28 This, in turn, augments the immunosuppressive actions of cyclosporine, which include attenuation of T-cell activity, reduction of monocyte chemotaxis, and downregulation of major histocompatibility complex-II gene expression. Our study revealed that the use of statins in heart transplant recipients resulted in 70% reduction in terminal cancer. This is consistent with findings by Fröhlich et al 9 showing that statin therapy is associated with 67% decrease in incidence of cancer. This benefit was not related to the dose of statin or intensity of cholesterol reduction. Statins influence metalloproteinases, enzymes that promote cell transformation. 6 Additionally, statins inhibit the production of dolichol, ubiquinol, farnesol and geranylgeraniol, all of which are involved in angiogenesis, tumor cell proliferation, and differentiation. 12, 13 These molecular mechanisms probably explain the reduction in incidence of cancer in heart transplant patients on statin therapy.
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Limitations
Our pooled analysis has several limitations. Because of the small sample size of relevant studies, we included the data from randomized controlled trials and nonrandomized studies. Inclusion of observational studies is associated with a potential bias, as the distribution of unmeasured confounding factors may not be similar between 2 comparison groups. Systematic reviews may have publication bias because of probability of publication of only positive studies or omission of pertinent studies from analysis. However, comprehensive literature search of multiple databases was performed, and publication bias was evaluated by Begg test and Egger regression test. The role of individual studies was examined by omitting 1 study at a time to evaluate the extent to which pooled analysis effect size depend on any single study (exclusion sensitivity analysis). Of note, the randomized controlled trials included in the pooled analysis were published more than 10 years ago, and medical care has changed during this time period. It is possible that the magnitude of benefit of statin therapy in the present era may not be exactly similar to that observed in the pooled analysis. However, care for these patients remains similar enough to conclude that benefit likely persists in the present day. Additionally, the majority of statins used in the clinical trials were those considered as moderate-or low-intensity statins. 30 It is conceivable that the use of high-intensity statins might provide additional benefit.
Conclusions
Evidence from the pooled analysis suggests that statins improve survival in heart transplant recipients. Additionally, statins may prevent fatal rejection episodes, decrease terminal cancer risk, and reduce the incidence of coronary vasculopathy. Further prospective studies are needed to further investigate and explain this association.
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METHODS
Protocol and registration 5
Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.
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Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
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Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
4-5
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
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Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 4
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2 ) for each meta-analysis.
